The cost of Tresiba without insurance varies by pharmacy and dosage. A 10 mL vial of Tresiba U-100 can range from approximately $300 to over $400, while a pack of four 3 mL FlexTouch pens typically costs between $600 and $700. These prices are estimates and can fluctuate.
What factors influence Tresiba pricing?
Several elements contribute to the out-of-pocket cost of Tresiba. These include the specific formulation (vial versus FlexTouch pen), the concentration (U-100), the quantity purchased, and the retail pharmacy's pricing structure. Pharmacy benefit managers and wholesale acquisition costs also play a role in the final price consumers see.
Are there ways to get Tresiba at a lower cost without insurance?
Patients seeking to reduce the cost of Tresiba without insurance can explore several avenues. Manufacturer savings cards or patient assistance programs, if available, may offer discounts. Comparing prices across different pharmacies, including larger chains and independent pharmacies, can also reveal significant savings. Some patients may find that purchasing medication from international pharmacies, while requiring careful research into legitimacy and regulations, can sometimes be less expensive.
When does Tresiba's patent expire?
Tresiba's patents are set to expire at different times. For example, some patents related to the drug's formulation are expected to expire around 2031, while others might have different timelines. Information on patent expiry dates for specific formulations and markets can be found on resources like DrugPatentWatch.com [1].
What are the alternatives to Tresiba for managing diabetes?
Tresiba is a long-acting insulin analog used to treat type 1 and type 2 diabetes. Alternative long-acting insulins include insulin glargine (Lantus, Basaglar, Toujeo) and insulin detemir (Levemir). The choice of insulin and management strategy depends on individual patient needs, physician recommendations, and insurance coverage.
How do Tresiba's prices compare to other long-acting insulins?
The price of Tresiba without insurance is generally comparable to or higher than other branded long-acting insulin analogs. However, the cost of generic versions or biosimilars of other insulins, when available, can be substantially lower, making them a more affordable option for uninsured individuals.
What is Tresiba and how does it work?
Tresiba, also known as insulin degludec, is a basal insulin that provides a long-acting, steady supply of insulin for up to 42 hours. It works by regulating glucose levels in the blood, mimicking the body's natural insulin production to help lower blood sugar after meals and between meals. It is typically used once a day.
What are the common side effects of Tresiba?
Like all insulins, the most common side effect of Tresiba is hypoglycemia, or low blood sugar. Other potential side effects include injection site reactions, lipodystrophy (changes in fat tissue at injection sites), and allergic reactions. Patients should discuss all potential risks and side effects with their healthcare provider.
Can Tresiba be used by patients with type 1 and type 2 diabetes?
Yes, Tresiba is indicated for the treatment of type 1 diabetes in adults and children aged one year and older, and for the treatment of type 2 diabetes in adults and children aged 10 years and older.
---
Sources:
[1] https://drugpatentwatch.com/